Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
-347.31%
726.53%
94.63%
53.36%
38.06%
29.07%
ROA
-79.43%
-86.14%
-168.81%
-182.41%
-195.22%
-201.2%
Gross Margin
100%
100%
100%
100%
100%
100%
Sector average
16.85%
17.71%
17.71%
17.71%
17.71%
17.71%
Net Margin
Amounts in SEK (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for IRLAB Therapeutics AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
-191.45%
-173.17%
-170.4%
-170.5%
-169.64%
-169.21%
Total Assets
SEK 140.80M
SEK 56.03M
SEK 59.01M
SEK 61.62M
SEK 64.17M
SEK 65.65M
Sector average
SEK 2,857.19M
SEK 2,900.24M
SEK 3,045.01M
SEK 3,280.29M
SEK 3,536.41M
SEK 3,762.91M
Net Income
-SEK 110.01M
-SEK 84.78M
-SEK 97.10M
-SEK 110.02M
-SEK 122.78M
-SEK 130.60M
Sector average
-SEK 2.85M
-SEK 22.03M
-SEK 0.90M
-SEK 7.25M
-SEK 3.86M
-SEK 1.55M
Valuation
SEK 292.96M
SEK 225.77M
SEK 258.59M
SEK 292.99M
SEK 326.96M
SEK 347.78M
Sector average
SEK 3,960.50M
SEK 5,151.30M
SEK 5,189.24M
SEK 5,317.34M
SEK 5,514.33M
SEK 5,636.78M
Stock Price
SEK 1.97
SEK 1.52
SEK 1.74
SEK 1.97
SEK 2.20
SEK 2.34
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
IRLAB Therapeutics AB (publ) (IRLAB-A.ST) Financial Forecast | Equlion
